Motilal Oswal has reiterated a BUY recommendation on Sun Pharma, assigning a target price of Rs 2,000, implying a 16% upside from its current market price of Rs 1,719.
Sun Pharmaceutical Industries has received a favorable legal ruling in the United States that clears a key hurdle in launching Leqselvi, its much-anticipated treatment for alopecia areata.
Sun Pharmaceutical and Zydus Lifesciences shares could see pressure on Monday as both companies have issued limited recall for some pharmaceutical products in the US market.
On Monday, domestic stock markets experienced a severe drop as the S&P BSE Sensex fell over 1,100 points in morning trade, eventually sliding 1,300 points to 78,420, while the NSE Nifty50 decli
